Vorinostat Rescues SQSTM1 Palmitoylation and Restores Dysfunctional Autophagy in Huntington Disease

This study demonstrates that the FDA-approved drug Vorinostat rescues Huntington disease pathology by restoring SQSTM1 palmitoylation, thereby correcting dysfunctional autophagy and reducing protein aggregation through a dual mechanism of inhibiting depalmitoylating enzymes and regulating gene transcription.

The Gist

The Big Picture: A Clogged Trash Can in the Brain

Imagine your brain cells are like busy kitchens. Every day, they cook up proteins (the ingredients) to keep the cell running. Sometimes, these proteins get "spoiled" or "broken" (misfolded). In a healthy kitchen, there is a dedicated trash system that grabs these broken items, puts them in a bag, and sends them to the garbage disposal (the lysosome) to be destroyed.

In Huntington's Disease (HD), this trash system breaks down. The broken proteins (specifically a toxic version of a protein called Huntingtin) pile up in the kitchen, forming sticky clumps that poison the cell. The cell tries to clean up, but the "trash collectors" can't grab the garbage properly, so the bags stay empty while the mess grows.

The Problem: The "Velcro" is Broken

The main trash collector in this story is a protein called SQSTM1 (or p62). Think of SQSTM1 as a specialized Velcro strap. Its job is to stick to the broken garbage (toxic proteins) and hook onto the trash bag (the autophagosome) to haul it away.

For this Velcro to work, it needs a special coating called palmitoylation. You can think of palmitoylation as the sticky glue on the Velcro.

• In a healthy brain: The glue is fresh and strong. The Velcro sticks, grabs the trash, and the garbage gets thrown away.
• In Huntington's Disease: The glue dries up and disappears. The Velcro becomes slippery. It can't grab the toxic trash, so the trash piles up, and the cell eventually dies.

The Discovery: A "Magic Wand" Drug

The researchers wanted to find a way to re-apply that sticky glue to the Velcro. They tested a list of drugs already approved by the FDA (drugs that are already known to be safe for humans) to see if any could fix this specific problem.

They found a winner: Vorinostat.

You might know Vorinostat as a cancer drug, but in this study, it acts like a magic glue gun. Here is what it does:

1. It crosses the barrier: The brain is protected by a high-security fence called the "Blood-Brain Barrier." Most drugs can't get in. Vorinostat is special because it can slip right through the fence and get into the brain.
2. It re-glues the Velcro: Once inside, Vorinostat stops the enzymes that are scraping the glue off the Velcro. It also tricks the cell into making more of the glue-making machines. The result? The Velcro (SQSTM1) gets its sticky coating back.
3. It clears the trash: With the glue restored, the Velcro can finally grab the toxic Huntingtin trash again. The trash bags fill up, fuse with the garbage disposal, and the toxic clumps are destroyed.

How They Proved It

The team didn't just guess; they ran experiments to watch this happen:

• In the Lab (Petri Dishes): They grew brain cells with Huntington's disease. When they added Vorinostat, the "glue" returned, and the cells started cleaning up their trash efficiently.
• In Mice: They treated mice that have a genetic version of Huntington's disease. After giving them Vorinostat, they looked at the mice's brains and saw that the glue was back, and the toxic trash was disappearing.
• The "Double-Action" Theory: The researchers think Vorinostat works in two ways at once:
  • Way A: It acts like a brake on the enzymes that remove the glue (stopping the glue from being scraped off).
  • Way B: It acts like a volume knob for the cell's instructions, turning up the volume on the genes that make the glue in the first place.

Why This Matters

This is exciting news for two reasons:

1. It targets the root cause: Instead of just trying to make the cell work harder, this drug fixes the specific mechanical failure (the missing glue) that causes the trash to pile up.
2. It's a known drug: Vorinostat is already FDA-approved and known to be safe for humans. This means that if these results hold up in larger trials, it could be repurposed to treat Huntington's disease much faster than inventing a brand-new drug from scratch.

In short: The researchers found a way to re-apply the "sticky glue" to the brain's trash collectors using an existing drug, allowing the brain to finally clean up the toxic mess that causes Huntington's disease.

Technical Summary

1. Problem Statement

Huntington Disease (HD) is characterized by protein mislocalization, dysfunctional autophagy, and the accumulation of toxic protein aggregates, specifically mutant huntingtin (mHTT). A critical defect in HD is the failure of cargo-loading during autophagy, where the autophagy receptor SQSTM1 (p62) fails to bind ubiquitinated cargo and deliver it to the phagophore membrane.

Previous research established that SQSTM1 palmitoylation (S-acylation) is significantly reduced in HD patient brains and mouse models (YAC128). Since palmitoylation is essential for the membrane localization of soluble proteins, this reduction prevents SQSTM1 from reaching autophagosomes, leading to empty autophagosomes and aggregate accumulation. While inhibiting depalmitoylating enzymes (like APT1) has shown promise, there is a need for a clinically viable, blood-brain barrier (BBB) permeable therapeutic that can restore this specific post-translational modification and rescue autophagic flux.

2. Methodology

The study employed a multi-faceted approach combining in vitro cell culture, in vivo mouse models, and computational analysis:

• Cell Models: HeLa cells (for biochemical assays) and primary cortical neurons derived from Wild-Type (WT) and YAC128 HD mouse embryos.
• Drug Treatment: Cells and mice were treated with Vorinostat (SAHA), an FDA-approved HDAC inhibitor. Comparisons were made against specific inhibitors: ML348 (APT1 inhibitor), Palmostatin B (PalmB) (broad depalmitoylase inhibitor), and 2-Bromopalmitate (2BP) (palmitoylation inhibitor).
• Biochemical Assays:
  • Acyl-Biotin Exchange (ABE): To specifically detect and quantify SQSTM1 and VCP palmitoylation levels.
  • Click Chemistry: To assess global protein palmitoylation dynamics using 15-hexadecynoic acid (15-HDYA).
  • Western Blotting: To measure levels of autophagy markers (SQSTM1, LC3-II) and loading controls.
• In Vivo Model: 22-month-old YAC128 transgenic mice received intraperitoneal (IP) injections of Vorinostat (50 mg/kg) every other day for four weeks. Cortical tissue was harvested for analysis.
• Microscopy: Confocal immunofluorescence microscopy was used to visualize the colocalization of SQSTM1, HTT, and lysosomes. Colocalization was quantified using the Pearson Correlation Coefficient (PCC).
• Mechanistic Investigation:
  • Molecular Docking: Used AutoDock Vina to predict Vorinostat's binding affinity to depalmitoylating enzymes (APT1, APT2).
  • qPCR: Analyzed transcript levels of ZDHHC enzymes (palmitoyltransferases), depalmitoylases (APT, PPT, ABHD), HDACs, and autophagy-related genes to determine transcriptional regulation.

3. Key Contributions

• Identification of Vorinostat: The study identifies Vorinostat, a known HDAC inhibitor, as a novel modulator that specifically increases SQSTM1 palmitoylation.
• BBB Penetration: Demonstrates that Vorinostat successfully crosses the blood-brain barrier and restores SQSTM1 palmitoylation in the cortices of HD mice in vivo.
• Dual Mechanism Proposal: Proposes a dual mode of action for Vorinostat:
  1. Direct or indirect inhibition of depalmitoylating enzymes.
  2. Transcriptional regulation (via HDAC inhibition) of key pathway components (increasing palmitoyltransferases and decreasing depalmitoylases).
• Restoration of Autophagic Flux: Shows that restoring SQSTM1 palmitoylation directly correlates with improved cargo loading and autophagic degradation of mHTT.

4. Key Results

A. Vorinostat Increases SQSTM1 Palmitoylation

• In Vitro: Treatment with Vorinostat significantly increased SQSTM1 palmitoylation in HeLa cells without altering total protein levels. Notably, it did not increase global protein palmitoylation, suggesting specificity for a subset of proteins like SQSTM1.
• In Vivo: In YAC128 mice, Vorinostat treatment significantly increased SQSTM1 palmitoylation in cortical tissue compared to vehicle-treated HD mice. It also increased VCP (valosin-containing protein) palmitoylation, another protein implicated in HD and autophagy.

B. Restoration of Autophagic Flux

• Marker Analysis: Vorinostat treatment led to a significant decrease in SQSTM1 levels and an increase in LC3-II levels, indicating enhanced autophagic flux (SQSTM1 is degraded in the lysosome, while LC3-II is recycled).
• Colocalization: Confocal microscopy revealed that Vorinostat significantly increased the colocalization of:
  • SQSTM1 with HTT.
  • SQSTM1 with lysosomes.
  • HTT with lysosomes.
• Specificity to HD: Crucially, these effects were observed in YAC128 neurons but not in WT neurons, suggesting Vorinostat selectively targets the pathological state of HD without disrupting normal autophagy in healthy cells. Vorinostat was more effective than ML348 or PalmB in redirecting both SQSTM1 and HTT to lysosomes.

C. Mechanism of Action

• Depalmitoylase Inhibition: Molecular docking showed Vorinostat binds to the active sites of APT1 and APT2, though with lower affinity than specific inhibitors (ML348/ML349). This suggests it may act as a weak inhibitor or that its effect is indirect.
• Transcriptional Regulation: qPCR analysis revealed Vorinostat treatment:
  • Increased transcripts of SQSTM1, ZDHHC11, and ZDHHC23 (palmitoyltransferases).
  • Decreased transcripts of LYPLA2 (APT2), PPT1, PPT2, and several ABHD enzymes (depalmitoylases).
  • This transcriptional shift favors a net increase in palmitoylation.

5. Significance and Conclusion

This paper provides a mechanistic link between SQSTM1 palmitoylation and autophagic dysfunction in Huntington Disease. It validates Vorinostat as a promising therapeutic candidate because:

1. It addresses the root cause: It corrects the specific post-translational defect (loss of palmitoylation) causing cargo-loading failure, rather than just stimulating autophagy non-specifically.
2. It is clinically translatable: Vorinostat is already FDA-approved and known to cross the BBB.
3. It offers a dual mechanism: By acting as both a potential depalmitoylase inhibitor and an HDAC inhibitor, it may simultaneously correct protein localization and transcriptional dysregulation, which are both hallmarks of HD.
4. Selectivity: The drug appears to rescue autophagy specifically in the diseased state (HD neurons) without over-activating it in healthy neurons, potentially reducing off-target toxicity.

The study concludes that targeting the palmitoylation status of SQSTM1 is a viable therapeutic strategy for HD, and Vorinostat represents a strong candidate for further development.